Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02001688 · ClinicalTrials.gov registry record · Phase 2
Phase II, Safety and Efficacy Study of Kamada-alpha-1-antitrypsin (AAT) for Inhalation"
A Phase 2 study, sponsored by Kamada.
- Completed
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
NCT02001688 is a Phase 2 study that has completed, run by Kamada. The registered enrollment target is 36 participants.
The verdict
NCT02001688, a Phase 2 study, has completed, sponsored by Kamada.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
Study Summary
To evaluate different doses of "Kamada-AAT for Inhalation" on the levels of alpha 1-proteinase inhibitor and other analytes in epithelial lining fluid (ELF) and serum and to assess the safety of the treatment in subjects with AAT Deficiency.
Interventions
- DRUG Placebo
- DRUG Kamada-AAT for Inhalation, 80mg
- DRUG Kamada-AAT for Inhalation, 160mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2014-04 |
| Est. Completion | 2016-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02001688
The ClinicalTrials.gov registry entry for NCT02001688 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kamada, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02001688 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02001688 about?
NCT02001688 is a clinical study titled "Phase II, Safety and Efficacy Study of Kamada-alpha-1-antitrypsin (AAT) for Inhalation"". To evaluate different doses of "Kamada-AAT for Inhalation" on the levels of alpha 1-proteinase inhibitor and other analytes in epithelial lining fluid (ELF) and serum and to assess the safety of the treatment in subjects with AAT Deficiency.
What is the current status of trial NCT02001688?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2014-04. Estimated completion is 2016-05.
What interventions are being tested in trial NCT02001688?
The interventions under investigation include: Placebo (DRUG), Kamada-AAT for Inhalation, 80mg (DRUG), Kamada-AAT for Inhalation, 160mg (DRUG).
Who is sponsoring clinical trial NCT02001688?
This trial is sponsored by Kamada, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.